Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab for Severe or Critical COVID-19 (Phase 2b/3)
2020-001996-33Phase 3Unknown
- Sponsor
- CytoDyn Inc.
- Start
- May 2020
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Leronlimab + standard of care with Placebo + standard of care (2 arms). Primary endpoint: All-cause mortality at Day 28. Status: unknown.
02
Drugs
leronlimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001996-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001996-33.